7 results on '"Chen, Xueqi"'
Search Results
2. The earliest optimal timing for total-body 68Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study.
- Author
-
Zheng, Zhe, Gao, Huaping, Lin, Yu, Yu, Haojun, Mao, Wujian, Yang, Runjun, He, Yibo, Chen, Xueqi, Wu, Ha, Hu, Pengcheng, and Shi, Hongcheng
- Subjects
POSITRON emission tomography ,WHOLE body imaging ,COMPUTED tomography ,SIGNAL-to-noise ratio - Abstract
Objectives: To investigate the earliest optimal timing for positron emission tomography (PET) scans after
68 Ga-fibroblast activation protein inhibitor-04 ([68 Ga]Ga-FAPI-04) injection. Methods: This prospective study enrolled patients who underwent 60-min dynamic68 Ga-FAPI-04 total-body PET/CT scans; the images were reconstructed at 10-min intervals (G0-10, G10-20, G20-30, G30-40, G40-50, and G50-60), and the [68 Ga]Ga-FAPI-04 uptake patterns were evaluated. The standardised uptake value (SUV), liver signal-to-noise ratio (SNR), and lesion-to-background ratios (LBRs) for different time windows were calculated to evaluate image quality and lesion detectability. The period from 30 to 40 min was then split into overlapping 5-min intervals starting 1 min apart for further evaluation. G50-60 was considered the reference. Results: A total of 30 patients with suspected malignant tumours were analysed. In the images reconstructed over 10-min intervals, longer acquisition times were associated with lower background uptake and better image quality. Some lesions could not be detected until G30-40. The lesion detection rate, uptake, and LBRs did not differ significantly among G30-40, G40-50, and G50-60 (all p > 0.05). The SUVmean and LBRs of primary tumours in the reconstructed images did not differ significantly among the 5-min intervals between 30 and 40 min; for metastatic and benign lesions, G34-39 and G35-40 showed significantly better SUVmean and LBR values than the other images. The G34-39 and G50-60 scans showed no significant differences in uptake, LBRs, or detection rates (all p > 0.05). Conclusion: The earliest optimal time to start acquisition was 34 min after injection of half-dose [68 Ga]Ga-FAPI-04. Clinical relevance statement: This study evaluated68 Ga-fibroblast activation protein inhibitor-04 ([68 Ga]Ga-FAPI-04) uptake patterns by comparing the image quality and lesion detection rate with 60-min dynamic [68 Ga]Ga-FAPI-04 total-body PET/CT scans and identified the earliest optimal scan time after [68 Ga]Ga-FAPI-04 injection. Key Points: • A prospective single-centre study showed that the earliest optimal time point to start acquisition was 34 min after injection of half-dose [68 Ga-fibroblast activation protein inhibitor-04 (68 Ga]Ga-FAPI-04). • There were statistically significant differences in standardised uptake value, lesion-to-background ratios, and lesion detectability between scans before and after 34 min from the injection of [68 Ga]Ga-FAPI-04, but these values did not change further from 34 to 60 min after injection. • With a reasonable acquisition time, the image quality could still meet diagnostic requirements. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. 18F‐FDG PET/CT findings of paratesticular alveolar rhabdomyosarcoma.
- Author
-
Chen, Xueqi, Shou, Jiayin, Li, Shanshi, Fan, Yan, and Zhang, Jianhua
- Subjects
- *
COMPUTED tomography , *POSITRON emission tomography , *POLYETHYLENE terephthalate , *RHABDOMYOSARCOMA , *SOFT tissue tumors , *AGGRESSION (Psychology) - Abstract
Rhabdomyosarcoma (RMS) originates from primitive mesenchymal cells and is the most common soft tissue tumor in childhood. 18F‐fluoro‐deoxyglucose (18F‐FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to be valuable in RMS staging and risk stratification. Paratesticular RMS is a relatively uncommon form of RMS, most of which are of the embryonal histologic type. Paratesticular alveolar RMS is associated with aggressive behavior, high metastatic potential, and poor outcomes. To the best of our knowledge, 18F‐FDG PET/CT imaging findings of paratesticular alveolar RMS have never been described. Here, we report on a 16‐year‐old boy's rare paratesticular alveolar RMS with multiple metastases and its findings on 18F‐FDG PET/CT. This case also demonstrates the potential value of 18F‐FDG PET/CT in RMS staging and treatment decisions, and may aid in the differential diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Noninvasive quantification of nonhuman primate dynamic 18F-FDG PET imaging.
- Author
-
Chen, Xueqi, Zhang, Sulei, Zhang, Jianhua, Chen, Lixin, Wang, Rongfu, and Zhou, Yun
- Subjects
- *
POSITRON emission tomography , *BLOOD sampling , *RHESUS monkeys , *PRIMATES , *SAMPLE size (Statistics) - Abstract
18F-FDG uptake rate constant Ki is the main physiology parameter measured in dynamic PET studies. A model-independent graphical analysis using Patlak plot with plasma input function (PIF) is a standard approach used to estimate Ki. The PIF is the 18F-FDG time activity curve (TAC) in plasma that is obtained by serial arterial blood sampling. The purpose of the study is to evaluate a Patlak plot-based optimization approach with reduced blood samples for noninvasive quantification of dynamic 18F-FDG PET imaging. Eight 60 min rhesus monkey brain dynamic 18F-FDG PET scans with arterial blood samples were collected. The measured PIF (mPIF) was determined by arterial blood samples. TACs of seven cerebral regions of interest were generated from each study. With a given number of blood samples, the population-based PIF (pPIF) was determined by either interpolation or extrapolation method using scale calibrated population mean of normalized PIF. The optimal sampling scheme with given blood sample size was determined by maximizing the correlations between the Ki estimated from pPIF and those obtained by mPIF. A leave-two-out cross-validation method was used for evaluation. The linear correlations between the Ki estimates from pPIF with optimal sampling schemes and those from mPIF were: Ki (pPIF 1 sample at 40 min) = 1.015 Ki (mPIF) − 0.000, R2 = 0.974; Ki (pPIF 2 samples at 35 and 50 min) = 1.052 Ki (mPIF) − 0.001, R2 = 0.976; Ki (pPIF 3 samples at 12, 40, and 50 min) = 1.030 Ki (mPIF) − 0.000, R2 = 0.985; and Ki (pPIF 4 samples at 10, 20, 40, and 50 min) = 1.016 Ki (mPIF)- 0.000, R2 = 0.993. As the sample size became greater or equal to 4, the Ki estimates from pPIF with the optimal protocol were almost identical to those from mPIF. The Patlak plot-based optimization approach is a reliable method to estimate PIF for noninvasive quantification of non-human primate dynamic 18F-FDG PET imaging and is potentially extendable to further translational human studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models.
- Author
-
Huo, Yan, Kang, Lei, Pang, Xiaoxi, Shen, Haoyuan, Yan, Ping, Zhang, Chunli, Liao, Xuhe, Chen, Xueqi, and Wang, Rongfu
- Subjects
POSITRON emission tomography ,CONFOCAL microscopy ,CHELATING agents ,FLOW cytometry - Abstract
Purpose: Tc-99m- and I-131-labeled arginine-arginine-leucine (RRL) peptides have shown the feasibility of tumor imaging in our previous studies. However, there have been no reports using RRL peptide for positron emission tomography (PET) imaging. In this study, RRL was radiolabeled with Ga-68 under optimized reaction conditions to develop a better specific and effective tumor imaging agent.Procedures: RRL was synthesized and conjugated to a bifunctional chelating agent (DOTA-NHS), then radiolabeled with Ga-68. Labeling yield was optimized by varying pH, temperature, and reaction time and the stability was evaluated in human fresh serum. Cellular uptakes of [68Ga]DOTA-RRL and FITC-conjugated RRL in HepG2 cells were evaluated using a gamma counter, confocal microscopy, and flow cytometry. PET images and biodistribution were performed in HepG2 tumor-bearing mice after injection of [68Ga]DOTA-RRL or [68Ga]GaCl3 at different time points. Further, blocking study was investigated using cold RRL.Results: The labeling yield of [68Ga]DOTA-RRL was 80.6 ± 3.9 % with a pH of 3.5-4.5 at 100 °C for 15 min. The cellular uptake of [68Ga]DOTA-RRL in HepG2 cells was significantly higher than that of [68Ga]GaCl3 (P < 0.05). Moreover, the high fluorescent affinity of FITC-conjugated RRL in HepG2 cells was shown using confocal microscopy and flow cytometry. After injection of [68Ga]DOTA-RRL in HepG2 tumor-bearing mice, tumor regions exhibited high radioactive accumulation over 120 min and the highest uptake at 30 min. After blocked with cold RRL, HepG2 tumors could not be visualized. [68Ga]GaCl3 was unable to show tumor images at any time point. The biodistribution results confirmed the PET imaging and blocking results.Conclusions: Our study successfully prepared [68Ga]DOTA-RRL with a high labeling yield under the optimized reaction conditions and demonstrated its potential role as a PET imaging agent for tumor-targeted diagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report.
- Author
-
Gao, Rui, Zhang, Guangjian, Chen, Xueqi, Yang, Aimin, Smith, Gwenn, Wong, Dean F., and Zhou, Yun
- Subjects
CEREBROSPINAL fluid ,PARKINSON'S disease ,BIOMARKERS ,ALPHA-synuclein ,AMYLOID beta-protein ,DISEASE progression ,STATISTICAL correlation - Abstract
Objective: Cerebrospinal fluid (CSF) biomarkers, such as α-synuclein (α-syn), amyloid beta peptide 1–42 (Aβ
1–42 ), phosphorylated tau (181P) (p-tau), and total tau (t-tau), have long been associated with the development of Parkinson disease (PD) and other neurodegenerative diseases. In this investigation, we reported the assessment of CSF biomarkers and their correlations with vesicular monoamine transporter 2 (VMAT2) bindings measured with18 F-9-fluoropropyl-(+)-dihydrotetrabenazine (18 F-AV133) that is being developed as a biomarker for PD. We test the hypothesis that monoaminergic degeneration was correlated with CSF biomarker levels in untreated PD patients. Methods: The available online data from the Parkinson’s Progression Markers Initiative study (PPMI) project were collected and analyzed, which include demographic information, clinical evaluations, CSF biomarkers (α-syn, Aβ1–42 , p-tau, and t-tau),18 F-AV133 brain PET, and T1 weighted MRIs. Region of interest (ROI) and voxel-wise Pearson correlation between standardized uptake value ratio (SUVR) and CSF biomarkers were calculated. Results: Our major findings are: 1) Compared with controls, CSF α-syn and tau levels decreased significantly in PD; 2) α-syn was closely correlated with Aβ1–42 and tau in PD, especially in early-onset patients; and 3) hypothesis-driven ROI analysis found a significant negative correlation between CSF Aβ1–42 levels and VMAT2 densities in post cingulate, left caudate, left anterior putamen, and left ventral striatum in PDs. CSF t-tau and p-tau levels were significantly negatively related to VMAT2 SUVRs in substantia nigra and left ventral striatum, respectively. Voxel-wise analysis showed that left caudate, parahippocampal gyrus, insula and temporal lobe were negatively correlated with Aβ1–42 . In addition, superior frontal gyrus and transverse temporal gyrus were negatively correlated with CSF p-tau levels. Conclusion: These results suggest that monoaminergic degeneration in PD is correlated with CSF biomarkers associated with cognitive impairment in neurodegenerative diseases including Alzheimer’s disease. The association between loss of dopamine synaptic function and pathologic protein accumulations in PD indicates an important role of CSF biomarkers in PD development. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression.
- Author
-
Chen, Xueqi, Zhou, Yun, Wang, Rongfu, Cao, Haoyin, Reid, Savina, Gao, Rui, Han, Dong, and null, null
- Subjects
- *
ALZHEIMER'S disease , *AMYLOID , *CEREBROSPINAL fluid , *BIOMARKERS , *FLUORODEOXYGLUCOSE F18 , *POSITRON emission tomography - Abstract
Objective: To evaluate the potential clinical value of quantitative functional FDG PET and pathological amyloid-β PET with cerebrospinal fluid (CSF) biomarkers and clinical assessments in the prediction of Alzheimer’s disease (AD) progression. Methods: We studied 82 subjects for up to 96 months (median = 84 months) in a longitudinal Alzheimer’s Disease Neuroimaging Initiative (ADNI) project. All preprocessed PET images were spatially normalized to standard Montreal Neurologic Institute space. Regions of interest (ROI) were defined on MRI template, and standard uptake values ratios (SUVRs) to the cerebellum for FDG and amyloid-β PET were calculated. Predictive values of single and multiparametric PET biomarkers with and without clinical assessments and CSF biomarkers for AD progression were evaluated using receiver operating characteristic (ROC) analysis and logistic regression model. Results: The posterior precuneus and cingulate SUVRs were identified for both FDG and amyloid-β PET in predicating progression in normal controls (NCs) and subjects with mild cognitive impairment (MCI). FDG parietal and lateral temporal SUVRs were suggested for monitoring NCs and MCI group progression, respectively. 18F-AV45 global cortex attained (78.6%, 74.5%, 75.4%) (sensitivity, specificity, accuracy) in predicting NC progression, which is comparable to the 11C-PiB global cortex SUVR’s in predicting MCI to AD. A logistic regression model to combine FDG parietal and posterior precuneus SUVR and Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) Total Mod was identified in predicating NC progression with (80.0%, 94.9%, 93.9%) (sensitivity, specificity, accuracy). The selected model including FDG posterior cingulate SUVR, ADAS-Cog Total Mod, and Mini-Mental State Exam (MMSE) scores for predicating MCI to AD attained (96.4%, 81.2%, 83.6%) (sensitivity, specificity, accuracy). 11C-PiB medial temporal SUVR with MMSE significantly increased 11C-PiB PET AUC to 0.915 (p<0.05) in predicating MCI to AD with (77.8%, 90.4%, 88.5%) (sensitivity, specificity, accuracy). Conclusion: Quantitative FDG and 11C-PiB PET with clinical cognitive assessments significantly improved accuracy in the predication of AD progression. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.